Clinical Trial

A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety and preliminary efficacy of SHR-7367 in combination with antineoplastic agents in subjects with advanced solid tumors, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-13.
Status change: Not Yet Recruiting → Recruiting 2025-12-18
Trial Details
NCT Number NCT07229586
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Solid Tumor
Enrollment 100 participants
Start Date 2025-12-02
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-19